These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 24862887)

  • 1. Nonoperative management of main pancreatic duct-involved intraductal papillary mucinous neoplasm might be indicated in select patients.
    Roch AM; DeWitt JM; Al-Haddad MA; Schmidt CM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    J Am Coll Surg; 2014 Jul; 219(1):122-9. PubMed ID: 24862887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
    Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
    Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
    JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential predictors of disease progression for main-duct intraductal papillary mucinous neoplasms of the pancreas.
    Ogura T; Masuda D; Kurisu Y; Edogawa S; Imoto A; Hayashi M; Uchiyama K; Higuchi K
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1782-6. PubMed ID: 23800049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology.
    Schmidt CM; White PB; Waters JA; Yiannoutsos CT; Cummings OW; Baker M; Howard TJ; Zyromski NJ; Nakeeb A; DeWitt JM; Akisik FM; Sherman S; Pitt HA; Lillemoe KD
    Ann Surg; 2007 Oct; 246(4):644-51; discussion 651-4. PubMed ID: 17893501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
    Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
    Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
    Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
    Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncocytic-type intraductal papillary mucinous neoplasms: a unique malignant pancreatic tumor with good long-term prognosis.
    Marchegiani G; Mino-Kenudson M; Ferrone CR; Warshaw AL; Lillemoe KD; Fernández-del Castillo C
    J Am Coll Surg; 2015 May; 220(5):839-44. PubMed ID: 25840549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules.
    Sadakari Y; Ienaga J; Kobayashi K; Miyasaka Y; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Pancreas; 2010 Mar; 39(2):232-6. PubMed ID: 19752768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
    Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
    Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
    Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
    J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological Meaning of Size of Main-Duct Dilatation in Intraductal Papillary Mucinous Neoplasm of Pancreas: Proposal of a Simplified Morphological Classification Based on the Investigation on the Size of Main Pancreatic Duct.
    Kang MJ; Jang JY; Lee S; Park T; Lee SY; Kim SW
    World J Surg; 2015 Aug; 39(8):2006-13. PubMed ID: 25894399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal serum pancreatic enzymes, but not pancreatitis, are associated with an increased risk of malignancy in patients with intraductal papillary mucinous neoplasms.
    Roch AM; Parikh JA; Al-Haddad MA; DeWitt JM; Ceppa EP; House MG; Nakeeb A; Schmidt CM
    Surgery; 2014 Oct; 156(4):923-9. PubMed ID: 25239347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate or observe?
    Jang JY; Kim SW; Lee SE; Yang SH; Lee KU; Lee YJ; Kim SC; Han DJ; Choi DW; Choi SH; Heo JS; Cho BH; Yu HC; Yoon DS; Lee WJ; Lee HE; Kang GH; Lee JM
    Ann Surg Oncol; 2008 Jan; 15(1):199-205. PubMed ID: 17909912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience.
    Yang AD; Melstrom LG; Bentrem DJ; Ujiki MB; Wayne JD; Strouch M; Bell RH; Rao SM; Talamonti MS
    Surgery; 2007 Oct; 142(4):529-34; discussion 534-7. PubMed ID: 17950345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas.
    Schnelldorfer T; Sarr MG; Nagorney DM; Zhang L; Smyrk TC; Qin R; Chari ST; Farnell MB
    Arch Surg; 2008 Jul; 143(7):639-46; discussion 646. PubMed ID: 18645105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas.
    Mimura T; Masuda A; Matsumoto I; Shiomi H; Yoshida S; Sugimoto M; Sanuki T; Yoshida M; Fujita T; Kutsumi H; Ku Y; Azuma T
    J Clin Gastroenterol; 2010 Oct; 44(9):e224-9. PubMed ID: 20453661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The distance of tumor spread in the main pancreatic duct of an intraductal papillary-mucinous neoplasm: where to resect and how to predict it.
    Okada K; Imaizumi T; Hirabayashi K; Matsuyama M; Yazawa N; Dowaki S; Tobita K; Ohtani Y; Kawaguchi Y; Tanaka M; Inokuchi S; Makuuchi H
    J Hepatobiliary Pancreat Sci; 2010 Jul; 17(4):516-22. PubMed ID: 20714841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraductal papillary mucinous neoplasm--when to resect?
    Waters JA; Schmidt CM
    Adv Surg; 2008; 42():87-108. PubMed ID: 18953811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.